PROGRAMAÇÃO CIENTÍFICA Sexta-feira - 15/06/18

Transcrição

1

2 PROGRAMAÇÃO CIENTÍFICA Sexta-feira - 15/06/18 10:30 às 12:30 Reunião dos grupos cooperativos (LACOG, GBECAM, EVA, GBOT, GTG). Apenas para convidados 13:00 às 14:00 Simpósio Satélite - Roche 14:00 Abertura 14:10 às 15:10 Módulo I GINECOLÓGICO Coordenadora: Aknar Calabrich (BA) 14:10 às 14:17 Abstract: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602 Palestrante: Andréia Cristina de Melo (RJ) 14:18 às 14:25 Abstract: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study. Palestrante: Angélica Nogueira Rodrigues (MG) 14:26 às 14:33 Abstract: Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B- MaNGO OV2B-ENGOT OV17 Palestrante: Daniela de Freitas (SP) 14:34 às 14:41 Abstract: Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel, Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab Palestrante: Maria Del Pilar Estevez Diz (SP) 14:42 às 15:10 Discussão 15:10 às 16:00 Módulo II MELANOMA Coordenador: Sérgio Jobin Azevedo (RS) 15:10 às 15:17 Abstract: Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study Palestrante: Andréia Cristina de Melo (RJ) 15:18 às 15:25 Abstract: Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node Palestrante: Sérgio Jobin Azevedo (RS) 15:25 às 15:32 Abstract: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). Palestrante: Rodrigo Guedes (BA) 15:33 às 15:40 Abstract: Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma Palestrante: Rodrigo R. Munhoz (SP) 15:40 às 16:00 Discussão 16:00 às 16:00 Coffee Break

3 16:30 às 18:00 Módulo III PULMÃO Coordenador: Artur Katz (SP) 16:30 às 16:40 Abstract: Efficacy and safety of rovalpituzumabtesirine in patients With DLL3-expressing, 3rd line small cell lung cancer: results from the Phase 2 TRINITY study. Abstract: DREAM: A Phase II study of Durvalumab with first line chemotherapy in Mesothelioma: First Results. Palestrante: Clarissa Mathias (BA) 16:41 às 16:51 Abstract: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. Abstract: Phase III study comparing bevacizumab plus erlotinib to erlotinibin patients with untreated NSCLC harboring activating EGFRmutations. NEJ026. Palestrante: Carolina Kawamura Haddad (SP) 16:52 às 16:59 Abstract: LBA IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab- Paclitaxel vs Carboplatin + nab-paclitaxel as 1L Therapy in Advanced Squamous NSCLC. Palestrante: Luiz Henrique de Lima Araújo (RJ) 17:00 às 17:07 Abstract: Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study. Palestrante: Mauro Zukin (RJ) 17:08 às 17:15 Abstract: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC). Palestrante: Ana Caroline Zimmer Gelatti (RS) 17:16 às 17:23 Abstract: LBA4 - Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as firstline therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. Palestrante: Clarissa Baldotto (RJ) 17:24 às 18:00 Discussão 18:00 às 19:00 Simpósio Satélite - Novartis 19:00 Apresentação dos Embaixadores do CURA 19:15 Coquetel de Abertura

4 PROGRAMAÇÃO CIENTÍFICA Sábado - 16/06/18 8:00 às 08:50 Simpósio Satélite LIBBS 8:50 às 10:00 Módulo V GENITOURINÁRIO Coordenador: Fernando Maluf (SP) 8:50 às 8:57 Abstract: LBA3 - CARMENA:Cytoreductivenephrectomyfollowedby sunitinib versus sunitinib alone in nmetastatic renal cell carcinoma Results of a phase III noninferiority trial Palestrante: Oren Smaletz (SP) 8:58 às 9:05 Abstract: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accrcc): results from cohort A of KEYNOTE-427 Palestrante: Fabio A. B. Schutz (SP) 9:06 às 9:13 Abstract: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial Palestrante: André Poisl Fay (RS) 9:14 às 9:21 Abstract: Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial Palestrante: Andrey Soares (SP) 9:22 às 9:29 Abstract: Olaparib combined with abiraterone in patients (pts) with metastatic castrationresistant prostate cancer (mcrpc): A randomized Phase II trial Palestrante: Igor Morbeck (DF) 9:30 às 10:00 Discussão 10:00 Coffee Break 10:30 Simpósio Satélite - NOVARTIS 11:30 às 13:00 Módulo VI MAMA Coordenador: Sérgio Simon (SP) Convidado Internacional: Otto Metzger (EUA) 11:30 às 11:37 Abstract: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Palestrante: José Bines (RJ) 11:38 às 11:45 Abstract: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. Palestrante: Rafael Kaliks (SP) 11:46 às 11:53 Abstract: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Palestrante: Max Mano (SP) 11:54 às 12:01 Abstract: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2 ) advanced breast cancer (ABC): Results from MONALEESA-3. Palestrante: Gustavo Werutsky (RS) 12:02 às 12:09 Abstract: LBA1 - TAILORx: Phase III trial of chemoendocrine therapy versus endocrinetherapyaloneinhormonereceptor- positive,her2-negative,nodenegativebreastcancer andanintermediateprognosis21-generecurrence score Palestrante: Sérgio Simon (SP)

5 12:10 às 12:17 Abstract: LBA Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA- mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. Palestrante: Tomas Reinert (RS) 12:18 às 12:25 Abstract: AZD5363 plus paclitaxel versus placebo plus paclitaxel às first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Palestrante: Daniela Dornelles Rosa (RS) 12:26 às 13:00 Discussão 13:00 às 14:00 Simpósio Satélite - ASTRAZENECA 14:00 às 15:00 Módulo VII CABEÇA E PESCOÇO Coordenador: William Nassib William Jr (SP) 14:00 às 14:07 Abstract: Resultsofa randomizedphaseiiistudyof Nimotuzumabin combinationwith concurrent radiotherapy and Cisplatinversus radiotherapy and Cisplatin alone in locally advanced squamous cell carcinoma of the head and neck Palestrante: Augusto Mota (BA) 14:08 às 14:15 Abstract: Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidhoffence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP) Palestrante: Aline Lauda Freitas Chaves (MG) 14:16 às 14:23 Abstract: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). Palestrante: Pedro de Marchi (SP) 14:24 às 14:31 Abstract: Multicenter Phase II Trial of Palbociclib, a Selective CyclinDependentKinase(CDK)4/6Inhibitor,and CetuximabinPlatinum-ResistantHPVUnrelated(-) Recurrent/MetastaticHeadandNeckSquamousCell Carcinoma (RM HNSCC). Palestrante: William Nassib William Jr (SP) 14:32 às 15:00 Discussão 15:00 Módulo VIII GASTROINTESTINAL + COLORRETAL Coordenador: Paulo Hoff (SP) Convidado Internacional: Caio Rocha Lima (EUA) 15:00 às 15:07 Abstract: Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5- fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer Palestrante: Rui Weschenfelder (RS) 15:08 às 15:15 Abstract: LBA A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. Palestrante: Fabio Ferreira (SP) 15:16 às 15:23 Abstract: First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab às maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mcrc): The VALENTINO study Palestrante: Fernanda Capareli (SP) 15:24 às 15:34 Abstract: KEYNOTE-164: Pembrolizumab for Patients With Advanced Microsatellite Instability High (MSI-H) Colorectal Cancer. Abstract: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. Palestrante: Jorge Sabbaga (SP) 15:35 às 15:42 Abstract: LBA Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mfolfirinox versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas Palestrante: Anelisa Coutinho (BA)

6 15:43 às 15:50 Abstract: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211) Palestrante: Rachel Riechelman (SP) 15:51 às 15:58 Abstract: LBA Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. Palestrante: Gabriel Prola (RS) 15:59 às 16:30 Discussão 16:30 às 18:00 Sessão Especial de Encerramento O que muda na prática Coordenador: Carlos Barrios (RS) 16: 30 às 16:45 Mama Palestrante: Otto Metzger (EUA) 16:45 às 17:00 Pulmão Palestrante: William Nassib William Jr (SP) 17:00 às 17:15 GI Palestrante: Caio Rocha Lima (EUA) 17:15 às 17:30 GU Palestrante: Fernando Maluf (SP) 17:30 às 18:00 Outros tumores e Discussão 18:00 Encerramento